Better survival of breast cancer patients with higher expression or lower promoter methylation of TAGLN, in addition to competence of its promoter methylation levels to discriminate cancer from healthy tissue, emphasize a possible clinical impact for this gene in breast cancer. The gene discussed is TAGLN; the disease is cancer.